PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Comparison of the efficacy of intravitreal ranibizumab for choroidal neovascularization due to pathological myopia with and without a dome-shaped macula.

Abstract Ranibizumab injection in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia (PM) with and without a dome-shaped macula (DSM).Prospective observational study.A total of 24 patients (24 eyes) with angiographic evidence of CNV secondary to PM were divided into 2 groups: eyes with a DSM and eyes without DSM. All patients received a baseline intravitreal ranibizumab injection. Additional injections were considered at each follow-up visit. Best-corrected visual acuity (BCVA) and optical coherence tomography were tested monthly through 12 months of follow-up. The mean changes in BCVA, central retinal thickness (CRT, including retinal and CNV thickness), and the number of injections were evaluated.There were no significant differences in visual outcomes between the groups over 12 months (P > .05). Patients with a DSM had a mean change in BCVA of +8.7 letters compared with +14.2 letters in patients without a DSM (P = .68). However, there were more patients without a DSM who gained at least 15 letters from baseline compared with patients with a DSM. By the end of the follow-up, there was no significant difference in the mean change in baseline CRT between patients with and without a DSM (-65.0 and -90.7, respectively, P = .42). The mean number of injections was 8.83 in the patients with DSM and 8.17 in the patients without a DSM (P > .05).For the pathological myopia patients who had CNV with a DSM, the DSM did not alter the effect of the ranibizumab treatment. There was no difference in the visual improvement, anatomic benefit and number of treatments between the 2 groups.
PMID
Related Publications

Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.

Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.

HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.

VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29390361
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20180212
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 50
DP  - 2017 Dec
TI  - Comparison of the efficacy of intravitreal ranibizumab for choroidal
      neovascularization due to pathological myopia with and without a dome-shaped
      macula.
PG  - e9251
LID - 10.1097/MD.0000000000009251 [doi]
AB  - Ranibizumab injection in the treatment of choroidal neovascularization (CNV)
      secondary to pathologic myopia (PM) with and without a dome-shaped macula
      (DSM).Prospective observational study.A total of 24 patients (24 eyes) with
      angiographic evidence of CNV secondary to PM were divided into 2 groups: eyes
      with a DSM and eyes without DSM. All patients received a baseline intravitreal
      ranibizumab injection. Additional injections were considered at each follow-up
      visit. Best-corrected visual acuity (BCVA) and optical coherence tomography were 
      tested monthly through 12 months of follow-up. The mean changes in BCVA, central 
      retinal thickness (CRT, including retinal and CNV thickness), and the number of
      injections were evaluated.There were no significant differences in visual
      outcomes between the groups over 12 months (P > .05). Patients with a DSM had a
      mean change in BCVA of +8.7 letters compared with +14.2 letters in patients
      without a DSM (P = .68). However, there were more patients without a DSM who
      gained at least 15 letters from baseline compared with patients with a DSM. By
      the end of the follow-up, there was no significant difference in the mean change 
      in baseline CRT between patients with and without a DSM (-65.0 and -90.7,
      respectively, P = .42). The mean number of injections was 8.83 in the patients
      with DSM and 8.17 in the patients without a DSM (P > .05).For the pathological
      myopia patients who had CNV with a DSM, the DSM did not alter the effect of the
      ranibizumab treatment. There was no difference in the visual improvement,
      anatomic benefit and number of treatments between the 2 groups.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Cai, Bincui
AU  - Cai B
AD  - Tianjin Medical University Eye Hospital, Tianjin, China.
FAU - Yang, Jin
AU  - Yang J
FAU - Li, Shuang
AU  - Li S
FAU - Wang, Linni
AU  - Wang L
FAU - Chen, Lu
AU  - Chen L
FAU - Li, Xiaorong
AU  - Li X
FAU - Li, Zhiqing
AU  - Li Z
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiogenesis Inhibitors)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - AIM
SB  - IM
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Choroidal Neovascularization/diagnostic imaging/*drug therapy/etiology
MH  - Female
MH  - Humans
MH  - Macula Lutea/*pathology
MH  - Male
MH  - Middle Aged
MH  - Myopia, Degenerative/*complications/diagnostic imaging
MH  - Prospective Studies
MH  - Ranibizumab/*therapeutic use
MH  - Tomography, Optical Coherence
MH  - Visual Acuity
EDAT- 2018/02/03 06:00
MHDA- 2018/02/13 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - 10.1097/MD.0000000000009251 [doi]
AID - 00005792-201712150-00111 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(50):e9251. doi: 10.1097/MD.0000000000009251.